Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status
Articolo
Data di Pubblicazione:
2018
Citazione:
Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status / C. Lunetta, A. Lizio, L. Tremolizzo, M. Ruscica, C. Macchi, N. Riva, P. Weydt, E. Corradi, P. Magni, V. Sansone. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 265:12(2018 Dec), pp. 3001-3008. [10.1007/s00415-018-9093-3]
Abstract:
Introduction The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able
to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism,
body weight and development and function of the nervous system.
Objectives (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the
possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features.
Methods We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy
controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a
normo-metabolic patient group (n=24) and a hyper-metabolic patient group (n=26).
Results ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0± 37.8 vs
13.1±2.2 ng/mL, p<0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normometabolic ALS patients and healthy controls (p<0.0009 and p<0.0001, respectively). Serum irisin levels showed significant
association with the ALSFRS-R (β=-1.18, p=0.042), Forced Vital Capacity (β = − 0.64, p=0.013), Fat Mass (β=-1.44,
p=0.034), pCO2 arterial blood levels (β=2.67, p=0.003), HCO3 − arterial blood levels (β=5.44, p=0.001) and Free Fat Mass (β=1.07, p=0.025) adjusted for sex, age and metabolic status.
Conclusions ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic
ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory
impairment, due to as yet unknown causes, being more elevated in patients with greater disability
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
ALS; Irisin; Metabolism; Myokine; Serum
Elenco autori:
C. Lunetta, A. Lizio, L. Tremolizzo, M. Ruscica, C. Macchi, N. Riva, P. Weydt, E. Corradi, P. Magni, V. Sansone
Link alla scheda completa: